Protein glycation products associate with progression of kidney disease and incident cardiovascular events in individuals with type 1 diabetes

Abstract Background Despite improved glycemic treatment, the impact of glycation on pathological consequences may persist and contribute to adverse clinical outcomes in diabetes. In the present study we investigated the association between serum protein glycation products and progression of kidney disease as well as incident major adverse cardiovascular events (MACE) in type 1 diabetes. Methods Fructosamine, advanced glycation end products (AGEs), and methylglyoxal-modified hydro-imidazolone (MG-H1) were measured from baseline serum samples in the FinnDiane study ( n = 575). Kidney disease progression was defined as steep eGFR decline (> 3 mL/min/1.73 m 2 /year) or progression of albuminuria (from lower to higher stage of albuminuria). MACE was defined as acute myocardial infarction, coronary revascularization, cerebrovascular event (stroke), and cardiovascular death. Results Fructosamine was independently associated with steep eGFR decline (OR 2.15 95% CI 1.16–4.01, p = 0.016) in the fully adjusted model (age, sex, baseline eGFR). AGEs were associated with steep eGFR decline (OR 1.58 per 1 unit of SD 95% CI 1.07–2.32, p = 0.02), progression to end-stage kidney disease (ESKD) (HR 2.09 per 1 unit of SD 95% CI 1.43–3.05, p < 0.001), and pooled progression (to any stage of albuminuria) (HR 2.72 per 1 unit of SD 95% CI 2.04–3.62, p < 0.001). AGEs (HR 1.57 per 1 unit of SD 95% CI 1.23–2.00, p < 0.001) and MG-H1 (HR 4.99 95% CI 0.98–25.55, p = 0.054) were associated with incident MACE. MG-H1 was also associated with pooled progression (HR 4.19 95% CI 1.11–15.89, p = 0.035). Most AGEs and MG-H1 associations were no more significant after adjusting for baseline eGFR. Conclusions Overall, these findings suggest that protein glycation products are an important risk factor for target organ damage in type 1 diabetes. The data provide further support to investigate a potential causal role of serum protein glycation in the progression of diabetes complications.